Zentalis Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 63.22 million compared to USD 59.08 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 1.31 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.87 USD | -0.84% | +5.32% | -21.65% |
05-29 | Zentalis Pharmaceuticals Announces Appointment of Luke Walker, M.D., to Board of Directors | CI |
05-24 | Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.65% | 844M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ZNTL Stock
- News Zentalis Pharmaceuticals, Inc.
- Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023